Genetic Evidence Links SGLT2i, GLP-1RA, and Metformin to Reduced Cardiovascular-Kidney-Metabolic Syndrome Risks
Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.
Abstract
Drug-target Mendelian randomization reveals genetic proxies for SGLT2i, GLP-1RA, and metformin reduce risks of CKM syndrome outcomes, while insulin and TZDs show increased risks.